AZ mulling over mixed data for Bevespi Aerosphere
AstraZeneca has announced mixed top-line results from the AERISTO Phase IIIb trial for Bevespi Aerosphere in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Read More
